CNS Pharmaceuticals, Inc. Logo

CNS Pharmaceuticals, Inc.

Biotech developing drugs that cross the blood-brain barrier for brain and CNS cancers.

CNSP | US

Overview

Corporate Details

ISIN(s):
US18978H1023
LEI:
Country:
United States of America
Address:
2100 WEST LOOP SOUTH, 77027 HOUSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's primary therapeutic focus is on glioblastoma multiforme (GBM), an aggressive and often incurable form of brain cancer. Its development pipeline features anti-cancer drug candidates, including its lead drug Berubicin, which are designed to cross the blood-brain barrier to effectively target brain malignancies. CNS Pharmaceuticals aims to advance transformative therapies through pioneering research to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CNS Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CNS Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CNS Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany
VVY
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210
Voyager Therapeutics, Inc. Logo
Developing AAV gene therapies for neurological diseases like Alzheimer's, ALS, and Parkinson's.
United States of America
VYGR
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
Vyome Holdings, Inc Logo
Develops therapies for inflammatory diseases and medical devices for obesity management.
United States of America
HIND
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE

Talk to a Data Expert

Have a question? We'll get back to you promptly.